Overview Dividends

(ANAB) AnaptysBio - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0327241065

Rosnilimab, ANB032, ANB033, ANB101, Imsidolimab

Biotechnology
Market Cap in USD: 1,399m
IPO / Inception: 2017-01-26
Return 12m vs S&P 500: 211%

EPS (Earnings per Share)

EPS (Earnings per Share) of ANAB over the last years for every Quarter: "2020-12": 1.2, "2021-03": -0.66, "2021-06": -0.02, "2021-09": -0.24, "2021-12": -1.13, "2022-03": -1.31, "2022-06": -1.15, "2022-09": -1.18, "2022-12": -0.93, "2023-03": -1.58, "2023-06": -1.5, "2023-09": -1.41, "2023-12": -1.59, "2024-03": -1.64, "2024-06": -1.71, "2024-09": -1.14, "2024-12": -0.72, "2025-03": -1.28, "2025-06": -1.34, "2025-09": 0.52, "2025-12": 0,
EPS CAGR: 39.39%
EPS Trend: 52.5%
Last SUE: -0.78
Qual. Beats: 0

Revenue

Revenue of ANAB over the last years for every Quarter: 2020-12: 60, 2021-03: 11.247, 2021-06: 30.027, 2021-09: 20.89, 2021-12: 1.010999, 2022-03: 0.97, 2022-06: 1.216, 2022-09: 1.293, 2022-12: 6.808, 2023-03: 1.374, 2023-06: 3.46, 2023-09: 3.318, 2023-12: 9.005, 2024-03: 7.179, 2024-06: 10.971, 2024-09: 30.017, 2024-12: 43.113, 2025-03: 27.771, 2025-06: 22.263, 2025-09: 76.32, 2025-12: null,
Rev. CAGR: 216.79%
Rev. Trend: 94.1%
Last SUE: 3.71
Qual. Beats: 1

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 66.7%
Value at Risk 5%th 84.6%
Relative Tail Risk -22.86%
Reward TTM
Sharpe Ratio 2.00
Alpha 261.18
CAGR/Max DD 0.25
Character TTM
Hurst Exponent 0.505
Beta 0.545
Beta Downside 0.311
Drawdowns 3y
Max DD 69.32%
Mean DD 31.84%
Median DD 33.13%

Description: ANAB AnaptysBio December 25, 2025

AnaptysBio, Inc. (NASDAQ: ANAB) is a clinical-stage biotech focused on immunology therapeutics, developing a portfolio of antibody programs that modulate T-cell activity and innate immune pathways.

Key pipeline assets include Rosnilimab (PD-1+ T-cell agonist/depletor), ANB032 (BTLA checkpoint inhibitor), ANB033 (anti-CD122 antagonist), ANB101 (BDCA2 modulator for plasmacytoid dendritic cells), and Imsidolimab (IL-36 receptor blocker) which is currently in Phase 3 for generalized pustular psoriasis.

The company’s strategic collaboration with GlaxoSmithKline provides an upfront payment of roughly $150 million and milestone potential exceeding $500 million, bolstering its cash position to about $150 million as of Q3 2025-sufficient for roughly 18 months of runway under current burn rates.

Sector-wide, immunology remains a high-growth segment, with global biologics sales projected to exceed $400 billion by 2028, driven by rising prevalence of autoimmune diseases and increasing payer acceptance of targeted therapies.

For a deeper quantitative view of ANAB’s valuation dynamics, you might explore ValueRay’s analytical tools.

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-84.6m TTM) > 0 and > 6% of Revenue (6% = 10.2m TTM)
FCFTA -0.41 (>2.0%) and ΔFCFTA -20.20pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 172.6% (prev 708.0%; Δ -535.4pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.41 (>3.0%) and CFO -145.0m <= Net Income -84.6m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 8.68 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (29.0m) change vs 12m ago 0.43% (target <= -2.0% for YES)
Gross Margin 9.72% (prev -170.7%; Δ 180.4pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 40.04% (prev 11.59%; Δ 28.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -0.09 (EBITDA TTM -4.57m / Interest Expense TTM 77.6m) >= 6 (WARN >= 3)

Altman Z'' -4.52

(A) 0.83 = (Total Current Assets 330.6m - Total Current Liabilities 38.1m) / Total Assets 353.1m
(B) -2.33 = Retained Earnings (Balance) -822.2m / Total Assets 353.1m
warn (B) unusual magnitude: -2.33 — check mapping/units
(C) -0.02 = EBIT TTM -6.99m / Avg Total Assets 423.3m
(D) -2.15 = Book Value of Equity -822.1m / Total Liabilities 382.5m
Total Rating: -4.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 25.33

1. Piotroski 0.50pt
2. FCF Yield -9.71%
3. FCF Margin -85.75%
4. Debt/Equity -11.78
5. Debt/Ebitda -51.78
6. ROIC - WACC (= -98.65)%
7. RoE data missing
8. Rev. Trend 94.08%
9. EPS Trend 52.51%

What is the price of ANAB shares?

As of January 01, 2026, the stock is trading at USD 48.48 with a total of 367,140 shares traded.
Over the past week, the price has changed by -3.06%, over one month by +17.36%, over three months by +58.33% and over the past year by +266.16%.

Is ANAB a buy, sell or hold?

AnaptysBio has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy ANAB.
  • Strong Buy: 7
  • Buy: 3
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ANAB price?

Issuer Target Up/Down from current
Wallstreet Target Price 65.1 34.3%
Analysts Target Price 65.1 34.3%
ValueRay Target Price 51.8 6.8%

ANAB Fundamental Data Overview December 27, 2025

Market Cap USD = 1.40b (1.40b USD * 1.0 USD.USD)
P/S = 8.2549
P/B = 114.7281
Beta = 0.293
Revenue TTM = 169.5m USD
EBIT TTM = -6.99m USD
EBITDA TTM = -4.57m USD
Long Term Debt = 14.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.04m USD (from shortTermDebt, last quarter)
Debt = 346.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 236.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.50b USD (1.40b + Debt 346.4m - CCE 249.0m)
Interest Coverage Ratio = -0.09 (Ebit TTM -6.99m / Interest Expense TTM 77.6m)
FCF Yield = -9.71% (FCF TTM -145.3m / Enterprise Value 1.50b)
FCF Margin = -85.75% (FCF TTM -145.3m / Revenue TTM 169.5m)
Net Margin = -49.94% (Net Income TTM -84.6m / Revenue TTM 169.5m)
Gross Margin = 9.72% ((Revenue TTM 169.5m - Cost of Revenue TTM 153.0m) / Revenue TTM)
Gross Margin QoQ = 58.85% (prev -69.90%)
Tobins Q-Ratio = 4.24 (Enterprise Value 1.50b / Total Assets 353.1m)
Interest Expense / Debt = 6.50% (Interest Expense 22.5m / Debt 346.4m)
Taxrate = 0.0% (0.0 / 15.1m)
NOPAT = -6.99m (EBIT -6.99m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 8.68 (Total Current Assets 330.6m / Total Current Liabilities 38.1m)
Debt / Equity = -11.78 (negative equity) (Debt 346.4m / totalStockholderEquity, last quarter -29.4m)
Debt / EBITDA = -51.78 (negative EBITDA) (Net Debt 236.6m / EBITDA -4.57m)
Debt / FCF = -1.63 (negative FCF - burning cash) (Net Debt 236.6m / FCF TTM -145.3m)
Total Stockholder Equity = 7.68m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.97% (Net Income -84.6m / Total Assets 353.1m)
RoE = -1101 % (out of range, set to none) (Net Income TTM -84.6m / Total Stockholder Equity 7.68m)
RoCE = -31.35% (EBIT -6.99m / Capital Employed (Equity 7.68m + L.T.Debt 14.6m))
RoIC = -90.93% (negative operating profit) (NOPAT -6.99m / Invested Capital 7.68m)
WACC = 7.72% (E(1.40b)/V(1.75b) * Re(8.02%) + D(346.4m)/V(1.75b) * Rd(6.50%) * (1-Tc(0.0)))
Discount Rate = 8.02% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 4.47%
Fair Price DCF = unknown (Cash Flow -145.3m)
EPS Correlation: 52.51 | EPS CAGR: 39.39% | SUE: -0.78 | # QB: 0
Revenue Correlation: 94.08 | Revenue CAGR: 216.8% | SUE: 3.71 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-1.07 | Chg30d=-0.066 | Revisions Net=-2 | Analysts=7
EPS next Year (2026-12-31): EPS=-4.05 | Chg30d=-0.402 | Revisions Net=-2 | Growth EPS=-181.6% | Growth Revenue=-37.7%

Additional Sources for ANAB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle